FI945416A0 - Dolastatiinijohdannaisia - Google Patents

Dolastatiinijohdannaisia

Info

Publication number
FI945416A0
FI945416A0 FI945416A FI945416A FI945416A0 FI 945416 A0 FI945416 A0 FI 945416A0 FI 945416 A FI945416 A FI 945416A FI 945416 A FI945416 A FI 945416A FI 945416 A0 FI945416 A0 FI 945416A0
Authority
FI
Finland
Prior art keywords
dolastatiinijohdannaisia
novel
dolastatin
derivates
formula
Prior art date
Application number
FI945416A
Other languages
English (en)
Swedish (sv)
Other versions
FI945416A (fi
FI120692B (fi
Inventor
Andreas Haupt
Franz Emling
Cynthia Romerdahl
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of FI945416A0 publication Critical patent/FI945416A0/fi
Publication of FI945416A publication Critical patent/FI945416A/fi
Application granted granted Critical
Publication of FI120692B publication Critical patent/FI120692B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FI945416A 1992-05-20 1994-11-17 Menetelmä syövänvastaisten dolastatiinijohdannaisten valmistamiseksi FI120692B (fi)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US88578892A 1992-05-20 1992-05-20
US88578892 1992-05-20
US98569692A 1992-11-25 1992-11-25
US98569692 1992-11-25
EP9301138 1993-05-10
PCT/EP1993/001138 WO1993023424A1 (en) 1992-05-20 1993-05-10 Derivatives of dolastatin

Publications (3)

Publication Number Publication Date
FI945416A0 true FI945416A0 (fi) 1994-11-17
FI945416A FI945416A (fi) 1994-11-17
FI120692B FI120692B (fi) 2010-01-29

Family

ID=27128772

Family Applications (1)

Application Number Title Priority Date Filing Date
FI945416A FI120692B (fi) 1992-05-20 1994-11-17 Menetelmä syövänvastaisten dolastatiinijohdannaisten valmistamiseksi

Country Status (21)

Country Link
EP (1) EP0642530B1 (fi)
JP (2) JP3523253B2 (fi)
KR (1) KR100286242B1 (fi)
CN (1) CN1065874C (fi)
AT (1) ATE169637T1 (fi)
AU (1) AU669710B2 (fi)
CA (1) CA2136339C (fi)
CZ (1) CZ292612B6 (fi)
DE (1) DE69320339T2 (fi)
DK (1) DK0642530T3 (fi)
ES (1) ES2118955T3 (fi)
FI (1) FI120692B (fi)
HU (2) HUT71398A (fi)
IL (1) IL105651A (fi)
MX (1) MX9302927A (fi)
NO (1) NO310465B1 (fi)
NZ (1) NZ252147A (fi)
RU (1) RU2116312C1 (fi)
SI (1) SI9300267A (fi)
UA (1) UA45304C2 (fi)
WO (1) WO1993023424A1 (fi)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5831002A (en) * 1992-05-20 1998-11-03 Basf Aktiengesellschaft Antitumor peptides
DE4415997A1 (de) * 1994-05-06 1995-11-09 Basf Ag Neuer peptidischer Wirkstoff und dessen Herstellung
DE4415998A1 (de) * 1994-05-06 1995-11-09 Basf Ag Neue Tetrapeptide, ihre Herstellung Verwendung
DE19527574A1 (de) * 1995-07-28 1997-01-30 Basf Ag Verfahren zur Herstellung vona-(N,N-Dialkyl)-aminocaarbonsäureamiden
DE19527575A1 (de) * 1995-07-28 1997-01-30 Basf Ag Verfahren zur Herstellung von peptidischer Wirkstoffe
US5807984A (en) * 1995-11-09 1998-09-15 Basf Aktienegesellschaft Oligopeptides, the preparation and use thereof
TW474946B (en) * 1995-12-15 2002-02-01 Basf Ag Novel compounds, the preparation and use thereof
AU775090B2 (en) * 1995-12-15 2004-07-15 Abbvie Deutschland Gmbh & Co Kg Antineoplastic peptides
US20010009901A1 (en) 1996-12-11 2001-07-26 Basf Aktiengesellschaft Germany Antineoplastic peptides
US5741892A (en) * 1996-07-30 1998-04-21 Basf Aktiengesellschaft Pentapeptides as antitumor agents
US5939527A (en) * 1996-07-30 1999-08-17 Basf Aktiengesellschaft Tetrapeptides as antitumor agents
US5965537A (en) * 1997-03-10 1999-10-12 Basf Aktiengesellschaft Dolastatin 15 derivatives with carbonyl and heterocyclic functionalities at the C-terminus
US6143721A (en) 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
WO1999015130A2 (en) * 1997-09-24 1999-04-01 ARIZONA BOARD OF REGENTS, actingon behalf of ARIZ ONA STATE UNIVERSITY Synthetic antineoplastic agents derived from dolastatin 15 and methods of making same
US6686445B1 (en) 1997-09-24 2004-02-03 Arizona Board Of Regents, Acting For And On Behalf Of Arizona State University Synthetic antineoplastic agents derived from dolastatin 15 and methods of making same
US5985837A (en) * 1998-07-08 1999-11-16 Basf Aktiengesellschaft Dolastatin 15 derivatives
ATE415413T1 (de) 2002-07-15 2008-12-15 Univ Princeton Iap-bindende verbindungen
ATE412409T1 (de) 2003-11-24 2008-11-15 Teva Gyogyszergyar Zartkoeruee Verfahren zur reinigung von pravastatin
WO2023033129A1 (ja) 2021-09-03 2023-03-09 東レ株式会社 癌の治療及び／又は予防用医薬組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879278A (en) * 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
ATE190983T1 (de) * 1991-08-09 2000-04-15 Teikoku Hormone Mfg Co Ltd Neue tetrapeptidderivate

Also Published As

Publication number Publication date
KR100286242B1 (ko) 2001-04-16
IL105651A0 (en) 1993-09-22
HU211745A9 (en) 1995-12-28
NO944419D0 (no) 1994-11-18
CN1065874C (zh) 2001-05-16
RU94046434A (ru) 1996-10-27
AU669710B2 (en) 1996-06-20
CZ284394A3 (en) 1995-05-17
DK0642530T3 (da) 1998-10-26
CN1085563A (zh) 1994-04-20
EP0642530B1 (en) 1998-08-12
JPH07506580A (ja) 1995-07-20
HUT71398A (en) 1995-11-28
RU2116312C1 (ru) 1998-07-27
IL105651A (en) 1998-07-15
SI9300267A (sl) 1993-12-31
WO1993023424A1 (en) 1993-11-25
CA2136339A1 (en) 1993-11-25
NO944419L (no) 1995-01-09
EP0642530A1 (en) 1995-03-15
JP3523253B2 (ja) 2004-04-26
DE69320339T2 (de) 1998-12-17
NZ252147A (en) 1996-10-28
NO310465B1 (no) 2001-07-09
CZ292612B6 (cs) 2003-11-12
MX9302927A (es) 1993-11-01
FI945416A (fi) 1994-11-17
ES2118955T3 (es) 1998-10-01
DE69320339D1 (de) 1998-09-17
UA45304C2 (uk) 2002-04-15
ATE169637T1 (de) 1998-08-15
AU4066293A (en) 1993-12-13
FI120692B (fi) 2010-01-29
JP2004149538A (ja) 2004-05-27
CA2136339C (en) 2008-02-05

Similar Documents

Publication Publication Date Title
DK0642530T3 (da) Dolastatinderivater
MY124487A (en) Dolastatin derivatives, their preparation and use
DE69329425D1 (de) Dolastatin analog
GR1000118B (el) Συνθεσις 1,2-διοξετανων & ενδιαμεσαι ουσιαι δι αυτην.
FI930051A0 (fi) 4,13-dioxabicyklo(8.2.1)tridecenonderivat sam foerfarande och mellanprodukt foer deras framstaellning
DE69012619T2 (de) Bis(1-Hydrocarbyloxy-2,2,6,6-tetramethylpiperidin-4-yl)-amin-derivate und stabilisierte Zusammensetzungen.
NZ228023A (en) 24(r)-scymnol; preparatory processes and pharmaceutical compositions
DK0570375T3 (da) Antikoagulatorisk virksomme peptider
MY114327A (en) Novel peptides, the preparation and use thereof
RU1809521C (ru) Генератор плазмы
ES2100257T3 (es) Acidos 2-arilpropenoicos y su uso para la preparacion de s-cetoprofeno.
TH14157EX (th) เฟนิลเบนแซมีดสำหรับฆ่าราและกรรมวิธีสำหรับเตรียมสารนั้น
FR2671122B3 (fr) Plaque d'etancheite.
TR199801087T2 (xx) 4,10 �- diasetoksi-2alfa-Benzoiloksi- 5 �, 20 epoksi-1- hidroksi-9- okso-19- norsiklopropa(G) taks-11- en- 13alfa-il
IT8821384A0 (it) 5 pirimidincarbossamidi sostituite e composizioni farmaceutiche contenenti le stesse per il trattamento di leucemia.
TR27159A (tr) Sübstitüe edilmis 2 -fenil-5-(3-fenoksifelin (1,1,1-trifloropentanlari hazirlamaya mahsus yöntem ve aramaddeler.
DK467689D0 (da) X1200 h.w.w. 683480

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 120692

Country of ref document: FI

MA Patent expired